PF-Atlas › Clinical Trials › NCT06951217

An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent

AP01 · ANZCTR · Phase 2

Registry ID
NCT06951217
Phase
Phase 2
Status
Recruiting
Drug / intervention
AP01
Mechanism
ANZCTR
Sponsor
Avalyn Pharma Inc.
Start
2025-04-17
Enrollment
340
Locations
72

About this trial

This is an open-label extension study for participants who were previously enrolled in and completed an Avalyn Pharma Sponsored study with an inhaled antifibrotic, such as AP01. Eligible participants will have their final dose of drug at the end of study visit from the lead-in study and first AP-LTE-008 study visit on the same day.

View NCT06951217 on ClinicalTrials.gov →

Explore related

All AP01 trialsANZCTR mechanismAll IPF trials

Related trials

AP01 — NCT06329401Ifenprodil — NCT04318704Inhaled mannitol — NCT00669331PTI-808 — NCT03251092BI 1819479 — NCT06335303CMS — NCT03093974
Medical disclaimer. This page summarizes public trial data for NCT06951217 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.